Ptc Therapeutics (PTCT) Income from Continuing Operations (2012 - 2026)

Ptc Therapeutics' Income from Continuing Operations history runs 15 years deep, the most recent figure standing at 2809000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations fell 100.32% year-over-year to 2809000.0; the TTM figure through Mar 2026 stood at 1425297000.0 (down 347.62% YoY), while the FY2025 annual figure was 555926000.0, down 45.33% from the prior year.
• Income from Continuing Operations was 2809000.0 for Q1 2026 at Ptc Therapeutics, up from 1373535000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 866562000.0 in Q1 2025 to a low of 1373535000.0 in Q4 2025.
• Historically, Income from Continuing Operations has averaged 80931823.53 across 5 years, with a median of 106654000.0 in 2024.
• Biggest YoY gain for Income from Continuing Operations was 1046.28% in 2025; the steepest drop was 1513.47% in 2025.
• A 5-year view of Income from Continuing Operations shows it stood at 204580000.0 in 2022, then surged by 407.44% to 628952000.0 in 2023, then plunged by 113.54% to 85129000.0 in 2024, then tumbled by 1513.47% to 1373535000.0 in 2025, then soared by 99.8% to 2809000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 2809000.0 (Q1 2026), 1373535000.0 (Q4 2025), and 15896000.0 (Q3 2025), per Business Quant data.